MedTrace Logo

JSP191 Antibody Targeting Conditioning in SCID Patients

NCT02963064 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-07-28

No results posted yet for this study

Summary

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation

Conditions

  • SCID

Interventions

BIOLOGICAL

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Procedure: single intravenous infusion of JSP191 antibody

Sponsors & Collaborators

  • Jasper Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Rajni A. Agarwal-Hashmi, M.D. · Lucile Packard Children's Hospital

  • Christopher C. Dvorak, M.D. · UCSF Benioff's Children's Hospital

  • Joseph H. Oved, M.D. · Memorial Sloan Kettering Cancer Center

  • Theodore B. Moore, M.D. · University of California, Los Angeles

  • Sharat Chandra, M.D. · Children's Hospital Medical Center, Cincinnati

  • Christen L Ebens, M.D., MPH · University of Minnesota

  • Harry L Malech, M.D. · National Institutes of Health Clinical Center (CC)

  • Shanmuganathan Chandrakasan, M.D. · Children's Healthcare of Atlanta

  • Neena Kapoor, M.D. · Children's Hospital Los Angeles

  • Elizabeth D Hicks, M.D. · Children's National Research Institute

  • Susan Prockop, M.D. · Boston Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-20
Primary Completion
2025-07-07
Completion
2025-07-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02963064 on ClinicalTrials.gov